LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Home・Akciju saraksts・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Slēgts

8.72 13.25

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

8.57

Max

8.86

Galvenie mērījumi
By Trading Economics
Ienākumi	4.2M -23M
Peļņas marža	-2,027.003
Darbinieki	83
EBITDA	6.6M -23M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+56.86% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	8.3M 595M
Iepriekšējā atvēršanas cena	-4.53
Iepriekšējā slēgšanas cena	8.72

Ventyx Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 19. dec. 17:29 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

2025. g. 19. dec. 16:47 UTC

Galvenie tirgus virzītāji

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

2025. g. 19. dec. 16:10 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

2025. g. 20. dec. 19:00 UTC

Peļņas

Consumer Confidence, Economic Activity Data, and a Short Trading Week for Christmas -- Barrons.com

2025. g. 19. dec. 22:33 UTC

Peļņas

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

2025. g. 19. dec. 22:19 UTC

Peļņas

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

2025. g. 19. dec. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025. g. 19. dec. 21:44 UTC

Peļņas

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025. g. 19. dec. 21:38 UTC

Peļņas

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

2025. g. 19. dec. 21:00 UTC

Tirgus saruna

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

2025. g. 19. dec. 20:23 UTC

Tirgus saruna

Oil Futures End Down Week on Up Note -- Market Talk

2025. g. 19. dec. 20:14 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

2025. g. 19. dec. 18:38 UTC

Tirgus saruna

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

2025. g. 19. dec. 18:00 UTC

Tirgus saruna

Peļņas

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

2025. g. 19. dec. 17:41 UTC

Peļņas

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025. g. 19. dec. 17:24 UTC

Tirgus saruna

Peļņas

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

2025. g. 19. dec. 17:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2025. g. 19. dec. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 19. dec. 16:29 UTC

Peļņas

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

2025. g. 19. dec. 16:20 UTC

Iegādes, apvienošanās, pārņemšana

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

2025. g. 19. dec. 16:19 UTC

Iegādes, apvienošanās, pārņemšana

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

2025. g. 19. dec. 16:18 UTC

Iegādes, apvienošanās, pārņemšana

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

2025. g. 19. dec. 16:16 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 19. dec. 16:16 UTC

Tirgus saruna

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

2025. g. 19. dec. 16:05 UTC

Iegādes, apvienošanās, pārņemšana

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025. g. 19. dec. 16:04 UTC

Iegādes, apvienošanās, pārņemšana

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025. g. 19. dec. 15:37 UTC

Tirgus saruna

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

2025. g. 19. dec. 15:21 UTC

Tirgus saruna

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

2025. g. 19. dec. 15:09 UTC

Tirgus saruna

Gold Flat But Set for Weekly Gains -- Market Talk

2025. g. 19. dec. 15:09 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Ventyx Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

56.86% augšup

Prognoze 12 mēnešiem

Vidējais 13.71 USD 56.86%

Augstākais 21 USD

Zemākais 2 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ventyx Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ventyx Biosciences Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.